Is Shionogi & Co., Ltd. (SGIOY) a Buy, Sell, or Hold?
OTC : SGIOY
Shionogi & Co., Ltd. — News
$8.9 USD
$0.03 (0.34%)
- Volume
- 1.24K
- Average Volume
- 146.12K
- Market Capitalization
- $15.15B
- P/E Ratio
- 9.08
- Dividend Yield
- 2.53%
- Price Target
- Year High
- $12.00
- Year Low
- $7.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.23
- Current Ratio
- $1.14
| Source | Headline |
|---|---|
|
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share. zacks.com - 2026-08-03 08:11:08 |
|
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2026-07-20 11:01:17 |
|
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare. businesswire.com - 2026-05-13 17:08:00 |
